SEC Form 4 · accession 0001193125-26-279779
Disc Medicine, Inc. · IRON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Quisel
Officer — Chief Executive Officer · Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 5:16 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001816736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | M | 34,000 | $9.86 | A | 260,064 | D | |
| Common StockF2 | Jun 18, 2026 | S | 22,927 | $69.9184 | D | 237,137 | D | |
| Common StockF3 | Jun 18, 2026 | S | 9,522 | $70.70 | D | 227,615 | D | |
| Common StockF4 | Jun 18, 2026 | S | 1,551 | $71.6126 | D | 226,064 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $9.86 | Jun 18, 2026 | M | 34,000 | D | — | Sep 13, 2031 | Common Stock | 34,000 | 41,375 | D |
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.35 to $70.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.36 to $71.35, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.36 to $71.85, inclusive.
- F5The shares underlying this option are fully vested and exercisable as of the date hereof.